ABCC2 and Hyperbilirubinemia: Although some drugs included in this study, as well as fasiglifam and silibinin, display comparatively potent inhibition of MRP2 in vitro, no cut-off for MRP2 inhibition predictive to hyperbilirubinemia has been suggested so far, and isolated inhibition of MRP2 without affectedness of other hepatic bilirubin transporters is unlikely to cause clinically relevant unconjugated hyperbilirubinemia.